VNRX | tickerfilter.com

Fundamental analysis

24%

Profitability 0%

Dept financing 29%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1,884.30%

1 Month

1,363.16%

3 Months

1,007.13%

6 Months

546.51%

1 Year

449.52%

2 Year

223.71%

Key data

Stock price

$2.78

P/E Ratio

0.00

DAY RANGE

$2.48 - $2.78

EPS

-$0.43

52 WEEK RANGE

$0.13 - $2.78

52 WEEK CHANGE

$479.17

MARKET CAP

73.036 M

YIELD

N/A

SHARES OUTSTANDING

122.802 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

1.66

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,106,620

AVERAGE 30 VOLUME

$3,649,867

Company detail

CEO: Cameron J. Reynolds
Region: US
Website: volition.com
Employees: 80
IPO year: 2011

Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

VolitionRx Limited engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; NuQ Nets, monitoring the immune system, and NuQ Vet cancer screening test for veterinary applications. The company operates Nucleosomics a technology platform.

VNRX - VOLITIONRX LTD